REG - Arecor Therapeutics - Grant of options and PDMR dealing

Arecor TherapeuticsAnnouncement

21/05/2026 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260521:nRSU2941Fa&default-theme=true

RNS Number : 2941F  Arecor Therapeutics PLC  21 May 2026

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

GRANT OF OPTIONS AND PDMR DEALING

 

Cambridge, UK, 21 May 2026: Arecor Therapeutics plc (AIM: AREC), a clinical
stage biotech company developing superior therapeutics that can reduce
treatment burden and improve outcomes for people living with diabetes, obesity
and other cardiometabolic diseases, announces that on 20 May 2026 (the "Grant
Date") the Company granted a total of 455,000 options under the Company's Long
Term Incentive Plan ("LTIP Options") over new ordinary shares of 1 pence each
in the Company ("Ordinary Shares").

 

Details of options granted to PDMRs are included in the table below.

 Name of individual  Job title                  Number of LTIP Options granted under 2026 award  Price (£)
 Sarah Howell        Chief Executive Officer    160,000                                          0.01
 David Ellam         Chief Financial Officer    105,000                                          0.01
 Jan Jezek           Chief Scientific Officer   95,000                                           0.01
 David Gerring       Chief Development Officer  95,000                                           0.01

 

The LTIP Options have an exercise price of 1 pence. Performance conditions
include both time (30% of the options granted) and Share Price Outperformance*
(70% of the options granted) during the three-year performance period. The
LTIP Options are subject to continued service and the extent to which the
performance conditions are satisfied. Vesting does not occur until the end of
the three-year performance period.  Vested LTIP Options will normally be
exercisable from after the end of the three-year performance period and until
the tenth anniversary of the Grant Date, after which time they will lapse if
not exercised. They are subject to a condition that the LTIP Options or the
Ordinary Shares acquired on exercise of the LTIP Options (other than those
sold to cover tax and National Insurance) are held for a minimum one-year
period from vesting.

*Outperformance when compared to the FTSE AIM All Share index.

 

The notifications below, made in accordance with the requirements of the
Market Abuse Regulation, provide further detail.

 

-ENDS-

 

For more information, please contact:

 

 Arecor Therapeutics plc                          +44 (0) 1223 426060

Dr Sarah Howell, Chief Executive Officer

David Ellam, Chief Financial Officer            info@arecor.com

 Singer Capital Markets Advisory LLP              +44 (0) 20 7496 3000

(NOMAD and Broker)
 Phil Davies, James Fischer

 Vigo Consulting (Financial Communications)       +44 (0) 20 7390 0230
 Melanie Toyne-Sewell, Rozi Morris

                                                  arecor@vigoconsulting.com

 Vida Strategic Partners (US Investor Relations)  +1 (415) 675-7401

 Stephanie Diaz                                   sdiaz@vidasp.com

Notes to Editors

 

Arecor Therapeutics plc is a clinical stage biotech company developing
superior therapeutics that can reduce treatment burden and improve outcomes
for people living with diabetes, obesity and other cardiometabolic diseases.

Its lead product is AT278, the only ultra-concentrated (500U/mL)
ultra-rapid-acting insulin, which enables disruptive drug delivery devices. It
is being co-developed with Sequel Med Tech, a company
commercialising state-of-the art insulin delivery devices. Arecor is also
developing a novel oral delivery platform for peptides with its first
validation target a GLP-1 receptor agonist.

The Company is quoted on AIM (AIM: AREC) and is based in Cambridge, UK. For
further details please see www.arecor.com (http://www.arecor.com/)

Arecor® and Arestat® are registered trademarks of Arecor Limited.

About AT278

AT278 is a novel proprietary formulation of an existing insulin, designed to
accelerate the absorption of insulin post injection even at very high
concentrations (500U/mL). With its best-in-class profile, it has the potential
to disrupt the market for insulin treatment as the first concentrated, yet
very rapid-acting-insulin for the growing population of people with diabetes
with high daily insulin needs as well as to act as a critical enabler in the
development of next-generation, miniaturised longer wear automated insulin
delivery (AID) systems.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

       Details of the person discharging managerial responsibilities/person closely
       associated
 a)    Name:                                                         1.    Sarah Howell

                                                                     2.    David Ellam

                                                                     3.    Jan Jezek

                                                                     4.    David Gerring
 2.    Reason for the notification
 a)    Position/status:                                              1.    Chief Executive Officer and Executive Director

                                                                     2.    Chief Financial Officer and Executive Director

                                                                     3.    Chief Scientific Officer

                                                                     4.    Chief Development Officer
 b)    Initial notification/Amendment:                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name:                                                         Arecor Therapeutics plc
 b)    LEI:                                                          98450093D12I3A8DDD58
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the financial instrument, type of instrument:  Ordinary shares of 1 pence each

       Identification code:

                                                                     GB00BMWLM973
 b)    Nature of the transaction:                                    Grant of awards over Ordinary Shares under the Company's Long Term Incentive
                                                                     Plan.
 c)    Price(s) and volume(s):                                       2026 LTIP Award
                                                                      Exercise Price(s) (£)    Volume(s)
                                                                     1.    £0.01               160,000

                                                                     2.    £0.01               105,000

                                                                     3.    £0.01               95,000

                                                                     4.    £0.01               95,000
 d)    Aggregated information:

       · Aggregated volume:                                          455,000

       · Price:                                                      £0.01
 e)    Date of the transaction:                                      20 May 2026
 f)    Place of the transaction:                                     Outside of a trading venue

d)

Aggregated information:

· Aggregated volume:

· Price:

 

455,000

£0.01

e)

Date of the transaction:

20 May 2026

f)

Place of the transaction:

Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHAKDBNCBKKQPB



            Copyright 2019 Regulatory News Service, all rights reserved